Hsp65-producing Lactococcus lactis prevents inflammatory intestinal disease in mice by IL-10- and TLR2-dependent pathways

Frontiers in Immunology

Volumn 8, Issue JAN, 2017, Pages

  Gomes Santos, Ana Cristina ^a,b   de Oliveira, Rafael Pires ^a,c   Moreira, Thaís Garcias ^a   Castro Junior, Archimedes Barbosa ^a   Horta, Bernardo Coelho ^a   Lemos, Luísa ^a   de Almeida, Leonardo Augusto ^a,d   Rezende, Rafael Machado ^a,e   Cara, Denise Carmona ^a   Oliveira, Sérgio Costa ^a   Azevedo, Vasco Ariston Carvalho ^a   Miyoshi, Anderson ^a   Faria, Ana Maria Caetano ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Instituto de Educação Continuada   (Brazil)

^c INSTITUTO FEDERAL DO PARANÁ   (Brazil)

^d FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Colitis; DSS; Hsp; IL 10; Lactococcus lactis; TLR2

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 65; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; XYLOSE; ZYMOSAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; LACTOCOCCUS LACTIS; LIPID ACCUMULATION PRODUCT INDEX; MOUSE; NONHUMAN; OPTICAL DENSITY;

EID: 85012183969     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00030     Document Type: Article

References (66)

1. Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol (2012) 5(3):232-9. doi: 10.1038/mi.2012.4
2. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev (2005) 204:184-94. doi:10.1111/j.0105-2896.2005.00250.x
3. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol (2012) 30:733-58. doi:10.1146/annurev-immunol-020711-075043
4. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature (2011) 474(7351):298-306. doi:10.1038/nature10208
5. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol (1997) 92(12 Suppl):5S-11S.
6. Podolsky DK. Inflammatory bowel disease. N Engl J Med (2002) 347(6):417-29. doi:10.1056/NEJMra020831
7. Sobczak M, Fabisiak A, Murawska N, Wesolowska E, Wierzbicka P, Wlazlowski M, et al. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep (2014) 66(5):766-75. doi:10.1016/j.pharep.2014.04.005
8. Rossi O, van Baarlen P, Wells JM. Host-recognition of pathogens and commensals in the mammalian intestine. Curr Top Microbiol Immunol (2013) 358:291-321. doi:10.1007/82_2011_191
9. Alexander KL, Targan SR, Elson CO III. Microbiota activation and regulation of innate and adaptive immunity. Immunol Rev (2014) 260(1):206-20. doi:10.1111/imr.12180
10. MacDonald TT. Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD). Clin Exp Immunol (1995) 102(3):445-7. doi:10.1111/j.1365-2249.1995.tb03835.x
11. Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity (2014) 40(6):843-54. doi:10.1016/j.immuni.2014.05.013
12. Jiang HQ, Thurnheer MC, Zuercher AW, Boiko NV, Bos NA, Cebra JJ. Interactions of commensal gut microbes with subsets of B-and T-cells in the murine host. Vaccine (2004) 22(7):805-11. doi:10.1016/j.vaccine.2003.11.022
13. Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res (2014) 7:113-20. doi:10.2147/JIR.S65979
14. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv Immunol (1999) 73:153-264. doi:10.1016/S0065-2776(08)60787-7
15. Lindquist S, Craig EA. The heat-shock proteins. Annu Rev Genet (1988) 22:631-77. doi:10.1146/annurev.ge.22.120188.003215
16. Borges JC, Ramos CH. Protein folding assisted by chaperones. Protein Pept Lett (2005) 12(3):257-61. doi:10.2174/0929866053587165
17. Walter S, Buchner J. Molecular chaperones - cellular machines for protein folding. Angew Chem Int Ed Engl (2002) 41(7):1098-113. doi:10.1002/1521-3773(20020402)41:7[1098::AID-ANIE1098]3.0.CO;2-9
18. Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. FASEB J (2003) 17(11):1567-9. doi:10.1096/fj.02-1139fje
19. Van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases. Ann N Y Acad Sci (2007) 1113:217-37. doi:10.1196/annals.1391.020
20. Stevens TR, Winrow VR, Blake DR, Rampton DS. Circulating antibodies to heat-shock protein 60 in Crohn's disease and ulcerative colitis. Clin Exp Immunol (1992) 90:271-4. doi:10.1111/j.1365-2249.1992.tb07941.x
21. Puga Yung GL, Fidler M, Albani E, Spermon N, Teklenburg G, Newbury R, et al. Heat shock protein-derived T-cell epitopes contribute to autoimmune inflammation in pediatric Crohn's disease. PLoS One (2009) 4(11):e7714. doi:10.1371/journal.pone.0007714
22. Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today (1991) 12(4):105-10. doi:10.1016/0167-5699(91)90093-9
23. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol (2005) 5(4):318-30. doi:10.1038/nri1593
24. Coelho V, Faria AM. HSP60: issues and insights on its therapeutic use as an immunoregulatory agent. Front Immunol (2011) 2:97. doi:10.3389/fimmu.2011.00097
25. Zanin-Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, Cohen IR. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest (2006) 116(7):2022-32. doi:10.1172/JCI28423
26. Wieten L, Berlo SE, Ten Brink CB, van Kooten PJ, Singh M, van der Zee R, et al. IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis. PLoS One (2009) 4(1):e4186. doi:10.1371/journal.pone.0004186
27. Ablamunits V, Elias D, Cohen IR. The pathogenicity of islet-infiltrating lymphocytes in the non-obese diabetic (NOD) mouse. Clin Exp Immunol (1999) 115(2):260-7. doi:10.1046/j.1365-2249.1999.00802.x
28. Zorzella-Pezavento SF, Chiuso-Minicucci F, Franca TG, Ishikawa LL, Martins DR, Silva CL, et al. Immunization with pVAXhsp65 decreases inflammation and modulates immune response in experimental encephalomyelitis. Neuroimmunomodulation (2010) 17(5):287-97. doi:10.1159/000292018
29. Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 106(13):1708-15. doi:10.1161/01.CIR.0000029750.99462.30
30. Rezende RM, Oliveira RP, Medeiros SR, Gomes-Santos AC, Alves AC, Loli FG, et al. Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. J Autoimmun (2013) 40:45-57. doi:10.1016/j.jaut.2012.07.012
31. Castro-Junior AB, Horta BC, Gomes-Santos AC, Cunha AP, Silva Steinberg R, Nascimento DS, et al. Oral tolerance correlates with high levels of lymphocyte activity. Cell Immunol (2012) 280(2):171-81. doi:10.1016/j.cellimm.2012.12.004
32. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev (2011) 241(1):241-59. doi:10.1111/j.1600-065X.2011.01017.x
33. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol (2006) 13(2-4):143-57. doi:10.1080/17402520600876804
34. Faria AM, Ficker SM, Speziali E, Menezes JS, Stransky B, Silva Rodrigues V, et al. Aging affects oral tolerance induction but not its maintenance in mice. Mech Ageing Dev (1998) 102(1):67-80. doi:10.1016/S0047-6374(98)00024-4
35. Faria AM, Maron R, Ficker SM, Slavin AJ, Spahn T, Weiner HL. Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. J Autoimmun (2003) 20(2):135-45. doi:10.1016/S0896-8411(02)00112-9
36. Oliveira RP, Santiago AF, Ficker SM, Gomes-Santos AC, Faria AM. Antigen administration by continuous feeding enhances oral tolerance and leads to long-lasting effects. J Immunol Methods (2015) 421:36-43. doi:10.1016/j.jim.2015.02.005
37. de Azevedo MS, Rocha CS, Electo N, Pontes DS, Molfetta JB, Gonçalves ED, et al. Cytoplasmic and extracellular expression of pharmaceutical-grade mycobacterial 65-kDa heat shock protein in Lactococcus lactis. Genet Mol Res (2012) 11(2):1146-57. doi:10.4238/2012.April.27.14
38. Cavanagh D, Fitzgerald GF, McAuliffe O. From field to fermentation: the origins of Lactococcus lactis and its domestication to the dairy environment. Food Microbiol (2015) 47:45-61. doi:10.1016/j.fm.2014.11.001
39. Mercadante AC, Perobelli SM, Alves AP, Gonçalves-Silva T, Mello W, Gomes-Santos AC, et al. Oral combined therapy with probiotics and alloantigen induces B cell-dependent long-lasting specific tolerance. J Immunol (2014) 192(4):1928-37. doi:10.4049/jimmunol.1301034
40. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289(5483):1352-5. doi:10.1126/science.289.5483.1352
41. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, et al. Orally administered L. lactis secreting an anti-TNF nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol (2010) 3(1):49-56. doi:10.1038/mi.2009.116
42. Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B, et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology (2007) 133(3):862-74. doi:10.1053/j.gastro.2007.06.018
43. de Azevedo MS, Electo N, Pontes DS, Machado JBM, Gonçalves EDC, Azevedo V, et al. Cytoplasmic and extracellular expression of pharmaceutical-grade mycobacterial 65 kDa heat shock protein in Lactococcus lactis. Genet Mol Res (2012) 11(2):1146-50. doi:10.4238/2012.April.27.14
44. Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A. Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Expr Purif (2011) 79(2):165-75. doi:10.1016/j.pep.2011.06.005
45. Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, Sedergran DJ. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci (1993) 38(9):1722-34. doi:10.1007/BF01303184
46. McCafferty DM, Sihota E, Muscara M, Wallace JL, Sharkey KA, Kubes P. Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol (2000) 279(1):G90-9.
47. Davies MD, Parrott DM. Preparation and purification of lymphocytes from the epithelium and lamina propria of murine small intestine. Gut (1981) 22(6):481-8. doi:10.1136/gut.22.6.481
48. Gomes-Santos AC, Moreira TG, Castro-Junior AB, Horta BC, Lemos L, Cruz DN, et al. New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol (2012) 2012:560817. doi:10.1155/2012/560817
49. Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol (2013) 4:185. doi:10.3389/fimmu.2013.00185
50. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75(2):263-74. doi:10.1016/0092-8674(93)80068-P
51. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol (2005) 175(6):3594-602. doi:10.4049/jimmunol.175.6.3594
52. Nishikawa M, Takemoto S, Takakura Y. Heat shock protein derivatives for delivery of antigens to antigen presenting cells. Int J Pharm (2008) 354(1-2):23-7. doi:10.1016/j.ijpharm.2007.09.030
53. Miao J, Niu J, Wang K, Xiao Y, Du Y, Zhou L, et al. Heat shock factor 2 levels are associated with the severity of ulcerative colitis. PLoS One (2014) 9(2):e88822. doi:10.1371/journal.pone.0088822
54. Ciancio MJ, Chang EB. Do heat shock proteins play any role in gut inflammation? Inflamm Bowel Dis (2008) 14(Suppl 2):S102-3. doi:10.1002/ibd.20697
55. Leung FW, Heng MC, Allen S, Seno K, Leung JW, Heng MK. Involvement of luminal bacteria, heat shock protein 60, macrophages and gammadelta T cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci (2000) 45(7):1472-9. doi:10.1023/A:1005545128954
56. Dasgupta A, Ramaswamy K, Giraldo J, Taniguchi M, Amenta PS, Das KM. Colon epithelial cellular protein induces oral tolerance in the experimental model of colitis by trinitrobenzene sulfonic acid. J Lab Clin Med (2001) 138(4):257-69. doi:10.1067/mlc.2001.118221
57. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology (2007) 132(4):1359-74. doi:10.1053/j.gastro.2007.02.056
58. Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity (2006) 25(2):319-29. doi:10.1016/j.immuni.2006.06.010
59. Tsan MF, Gao B. Endogenous ligands of toll-like receptors. J Leukoc Biol (2004) 76(3):514-9. doi:10.1189/jlb.0304127
60. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of toll-like receptor signalling complexes. Nat Rev Immunol (2014) 14(8):546-58. doi:10.1038/nri3713
61. Borges TJ, Lopes RL, Pinho NG, Machado FD, Souza AP, Bonorino C. Extracellular Hsp70 inhibits pro-inflammatory cytokine production by IL-10 driven down-regulation of C/EBPβ and C/EBPd. Int J Hyperthermia (2013) 29(5):455-63. doi:10.3109/02656736.2013.798037
62. Sato M, Sano H, Iwaki D, Kudo K, Konishi M, Takahashi H, et al. Direct binding of toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol (2003) 171(1):417-25. doi:10.4049/jimmunol.171.1.417
63. Shields AM, Panayi GS, Corrigall VM. Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis? Clin Exp Immunol (2011) 165:292-300. doi:10.1111/j.1365-2249.2011.04433.x
64. Motta A, Schmitz C, Rodrigues L, Ribeiro F, Teixeira C, Detanico T, et al. Mycobacterium tuberculosis heat-shock protein 70 impairs maturation of dendritic cells from bone marrow precursors, induces interleukin-10 production and inhibits T-cell proliferation in vitro. Immunology (2007) 121(4):462-72. doi:10.1111/j.1365-2567.2007.02564.x
65. de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol (2004) 172(10):6435-43. doi:10.4049/jimmunol.172.10.6435
66. Borges TJ, Wieten L, van Herwijnen MJ, Broere F, van der Zee R, Bonorino C, et al. The anti-inflammatory mechanisms of Hsp70. Front Immunol (2012) 4(3):95. doi:10.3389/fimmu.2012.00095